FDA Grants Traditional Approval to Encorafenib for mCRC with a BRAF V600E Mutation By Ogkologos - March 11, 2026 245 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the BREAKWATER study Source RELATED ARTICLESMORE FROM AUTHOR Ovarian Reserve Better Indicator of Adjuvant Chemotherapy Benefit than Self-Reported Menopause Status, Age, or Other Hormone Levels Immune-Modulating SBRT Plus Anti-PD-L1 May Convert Immune-Cold ER-positive, HER2-negative EBC Into More Inflamed Tumours and Improve Response EMA Recommends Extension of Therapeutic Indications for Serplulimab MOST POPULAR Adding Blinatumomab to Chemotherapy Improves DFS in Patients with Newly Diagnosed... January 13, 2025 Amid Coronavirus Outbreak and Panic Buying, Stores Introduce Special Shopping Times... March 18, 2020 FDA Approves Niraparib and Abiraterone Acetate Plus Prednisone for BRCA-mutated Metastatic... August 25, 2023 ‘Levelling Up’: What should it mean for cancer? February 2, 2022 Load more HOT NEWS Personalised blood test could help predict which lung cancers might return Prising open the trap: Getting to grips with targeted cancer drug... Dabrafenib–Trametinib Combination Approved for Melanoma, Anaplastic Thyroid Cancer ESMO Issues First Recommendations on Using Next-Generation Sequencing for Advanced Cancers...
